Novadip: Novadip Biosciences announced significant clinical milestones for both of its clinical stage programs

Novadip Biosciences announced that the first U..S patient has been implanted with its investigational tissue regeneration product, NVD 003, in its Phase 1b/2a clinical trial in Congenital Pseudarthrosis of Tibia (CPT), a rare pediatric bone condition. An autologous therapy derived from a patient's own adipose stem cel...